miércoles, 2 de febrero de 2022

HER2+ metastatic breast cancer: addition of tucatinib to trastuzumab plus capecitabine boosts survival

HER2+ metastatic breast cancer: addition of tucatinib to trastuzumab plus capecitabine boosts survival

No hay comentarios:

Publicar un comentario